Pharming Group NV is raising more than €25 million and converting €5.8 million of debt to equity. The Dutch biotechnology firm, which has struggled financially and emerged from court protection in October 2002, plans to use proceeds for general corporate purposes and to continue development of its lead product, a recombinant form of human C1 inhibitor (rhC1INH). (BioWorld International) Read More
